pulmonary mucosa-associated lymphoid tissue lymphoma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are eligible. 1. Patients who were histologically diagnosed with MALT lymphoma between January 1, 2013 and December 31, 2022 2. Patients who have involvement of the lung (lung biopsy is not mandatory)
Exclusion criteria
Exclusion criteria: Patients with one or more of the following are excluded. 1. Patients who were diagnosed as not pulmonary MALT lymphoma based on diagnosis-related information 2. Patients who refused to consent to opt-out
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival of patients with newly-diagnosed pulmonary MALT lymphoma diagnosed between 2013 and 2022 at participating institutes | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical features, treatment choice, toxicity, and risk factors affecting survival in pulmonary MALT lymphoma patients diagnosed between 2013 and 2022 at participating institutes | — |
Countries
Japan
Contacts
Mie University Graduate School of Medicine Department of Hematological Malignancies